The diagnosis and treatment of multiple myeloma has changed dramatically in the past
decade. The disease definition has been updated to include highly specific biomarkers in …

Background Pneumocystis pneumonia (PCP) is a disease affecting immunocompromised
patients. PCP among these patients is associated with significant morbidity and mortality …

Infections are a major cause of morbidity and mortality in patients with multiple myeloma. To
estimate the risk of bacterial and viral infections in multiple myeloma patients, we used …

Abstract The European Myeloma Network provides recommendations for the management
of the most common complications of multiple myeloma. Whole body low-dose computed …

Recent developments have led to remarkable improvements in the assessment and
treatment of patients with multiple myeloma (MM). New technologies have become available …

Secondary immunodeficiency is reported in most patients with hematological malignancies
such as chronic lymphocytic leukemia and multiple myeloma. The aim of our review was to …

Background Myeloma causes profound immunodeficiency and recurrent, serious infections.
Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of …

Secondary immunodeficiencies occur as a consequence of various diseases, including
hematological malignancies, and the use of pharmacological therapies, such as …

Infections are a major cause of morbidity and mortality in multiple myeloma. The increased
risk for bacterial and viral infections results mainly from the disease‐inherent and treatment …

The introduction of new therapeutic agents in multiple myeloma (MM), including proteasome
inhibitors, immunoregulatory drugs and monoclonal antibodies, has improved the outcomes …